BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
|Articles|July 1, 2017
- Pharmaceutical Executive-07-01-2017
- Volume 37
- Issue 7
Pharmaceutical Executive, July 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Building a Digital Health Infrastructureover 9 years ago
Patient Insights in the Age of AIover 9 years ago
Pharma Raises Stakes in Digital Healthover 9 years ago
Removing Uncertainty from the Drug Insurance Conversationover 9 years ago
Reflections from DIAover 9 years ago
Can AI Improve Sales Productivity in Pharma?over 9 years ago
Improving Patients’ Lives and Boosting Mature Product Portfoliosover 9 years ago
Reinventing the Role of Medical Affairsover 9 years ago
Beyond KOL Marketing: Tapping Digital Opinion Influencersover 9 years ago
There’s a Digital Health App for That!Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5